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Abstract
Objectives: To assess and compare the accuracy and inter-observer agreement for the detection of
liver lesions using Primovist magnetic resonance imaging (pMRI) and computed tomography during
arterial portography (CTAP).
Methods: Patients evaluated at St George Hospital Liver Unit for colorectal liver metastases (CRCLM)
underwent CTAP as part of standard staging. pMRI was added to the pre-operative assessment. Two
radiologists reported CTAP and two reported pMRI. The sensitivity and specificity of CTAP and pMRI
were calculated using histopathology as the gold standard.
Results: Complete data were available for 62 patients corresponding to 219 lesions confirmed on his-
topathology. Agreement on the detection of lesions between the two radiologists that reported pMRI
was higher than for CTAP (Kappa = 0.80 versus 0.74). Specificity of lesion detection for pMRI was
0.88 and 0.83 for CTAP (P = 0.112). Sensitivity for pMRI was 0.83 and 0.81 for CTAP. For patients
who had chemotherapy before evaluation, pMRI had a significantly higher specificity than CTAP (0.79
versus 0.63, P = 0.011).
Conclusions: pMRI is less invasive, has a good inter-observer agreement, has comparable sensitivity
and specificity to CTAP in the pre-chemotherapy population and demonstrates better specificity in
patients assessed post-chemotherapy. pMRI is a valid alternative to CTAP in the assessment of
CRCLM.
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Introduction
Background
Colorectal cancer is responsible for 10% of solid tumour can-
cer deaths in the western world.1 Liver metastases occur in
60% of patients after resection of colorectal cancer and a liver
resection remains the only curative option for these patients.
Several large series report 5-year survival after a curative liver
resection of 25% to 44%, with an operative mortality of 0% to
6.6%.2 Currently there is no consensus on the optimal
approach to pre-operative staging of patients with colorectal
liver metastases (CRCLM).2
Community equipoise exists regarding the best approach to
assess CRCLM. The UK guidelines for resection of CRCLM
allow that centres perform liver-specific imaging by local pro-
tocol,2 in the absence of clear evidence to support any one
approach. Each imaging modality has advantages and disad-
vantages related to cost, the speed of acquisition, the use of
The clinical trial is registered with the Australia and New Zealand
Clinical Trials Registry (ANZCTR.org.au), approved by the International
Committee of Medical Journal Editors (ICMJE). The registration number
is ACTRN1211000549921.
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ionizing radiation, the risk of contrast reaction, and local avail-
ability and expertise.
In the early 1990s, data from the USA and France showed
significantly better detection rates for computed tomography
during arterial portography (CTAP) at 93% compared to 75%
for combined ultrasound and dynamic CT.3,4 CTAP involves
selective angiographic catheterization of the superior mesen-
teric or splenic artery (Fig. 1). A bolus of contrast via the
artery enhances the liver parenchyma when returning via the
portal venous system. CRCLM appear hypodense as they are
predominantly supplied by arterial blood while 70% of the
liver’s blood supply is from the portal vein, and only 30%
originates from the hepatic artery.5 Although sensitive, this
technique is invasive and has a high false positive rate of 15%
on a per patient basis.5
Subsequent studies have acknowledged the improvements in
helical CT with intravenous contrast and suggest that with the
complementary benefit of intra-operative ultrasound (IOUS),
these are equivalent to CTAP in the assessment of CRCLM.6,7
However, the range of management strategies currently avail-
able for CRCLM makes accurate pre-operative assessment of
the full extent of disease important.2,8–10
In recent years, MRI has been used in liver imaging because
of its high specificity and superior sensitivity regarding lesion
detection and characterization in comparison to CT.11–13
The use of hepatobiliary-specific contrast has further
improved the accuracy of MRI. Hepatobiliary-specific agents
such as Primovist* (gadoxetic acid) are taken up by function-
ing hepatocytes and excreted in bile. Primovist provides early
strong intravascular contrast, facilitating dynamic phase
CTAP pMRI
(A)
(B)
(C)
Figure 1 Perfusion defects seen on computed tomography during arterial portography (CTAP) ( arrows) can be clarified on magnetic
resonance imaging (MRI) where there is better intrinsic soft tissue contrast. Some of the lesions in the right lobe seen on hepatobiliary
phase MRI/CTAP ( arrows) are not well seen on the portal venous phase of CTAP owing to perfusional abnormality
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imaging owing to its distribution in the extracellular fluid
compartment. Approximately 50% is subsequently taken up by
hepatocytes, and excreted into biliary canaliculi providing
robust delayed hepatic biliary tree imaging at 20 min post
injection, with persistent enhancement for more than 2 h,13–15
thus providing a dual function of dynamic imaging capability
as well as delayed hepatobiliary imaging.15,16
Although pMRI for the assessment of CRCLM has been
compared with other imaging modalities, there are no data
comparing pMRI with CTAP.17–20
The enthusiastic adoption of pMRI by some units suggests a
need for more accurate, non-invasive staging of CRCLM than
has been available in most centres to date.
pMRI has been shown to have sensitivity equivalent to
CTAP and better specificity, although the two tests have never
been directly compared. There is an appreciable false-positive
rate associated with CTAP (Figs 1 and 2). This is important as
it may result in a decision against curative surgery in favour of
palliative chemotherapy, ablation or regional treatments, all of
which while useful, are not as effective as resection in achieving
long-term survival in appropriately selected patients.21 There
is, therefore, a need to clarify the accuracy Primovist MRI can
provide in CRCLM assessment compared with the current
standard of CTAP.
The aim of the study was to assess and compare the accu-
racy and inter-observer agreement for detection of liver lesions
using Primovist MRI (pMRI) and CTAP.
The secondary aim was to assess the accuracy of detection
and characterization of liver lesions in patients who received
neoadjuvant chemotherapy by comparing the sensitivity and
specificity of Primovist MRI and CTAP in this subset.
Patients and methods
Patients
Patients with CRCLM considered suitable for a liver resection
aged between 18 and 85 years were eligible for inclusion.
Patients with renal impairment (eGFR < 30 ml/min) were
excluded, as this is a contraindication to CTAP and pMRI. For
CTAP, patients with eGFR 30–60 ml/min carries an intermedi-
ate risk of contrast-induced nephropathy, and these patients
were prehydrated as per routine protocol for CTAP. Patients
were also excluded if they had poor English and were unable
to use the help of an interpreter.
All patients had the routine workup for CRCLM, including
CT chest with a CTAP of the abdomen as well as a PET scan.
pMRI was added to the pre-operative assessment. More details
on the CTAP and pMRI protocols are given in the supporting
information for online publication (SIOP) 1 and 2.
At operation, intra-operative evaluation with inspection,
palpation and IOUS was performed.
Raters
Four radiologists experienced in hepatobiliary reporting partici-
pated in the study. The two more familiar with liver MRI were
asked to report the pMRI, whereas the other two radiologists
reported CTAP, and they were blind to the other radiology exam.
Gold standard and data collection protocol
Demographic data and clinical history were collected for all
patients. Each radiologist reported the lesions identifiable by
the allocated radiology exam, as well as characterization and
segmental location in the liver, according to Couinaud classifi-
cation.22
The gold standard for lesion identification was histopathol-
ogy. The details on pathology protocol are given in the SIOP 3.
Pathologists were required to examine specimens with a fine-cut
protocol to identify all small lesions to provide information for
assessment of the false-negative rate of the two radiology tests.
In patients where lesions were not resected after identification,
but rather treated with radiofrequency ablation at surgery, histo-
pathology is not available but for the purpose of diagnostic test
accuracy evaluation these lesions were assumed to be CRCLM.
Neoadjuvant treatment
Where staged or delayed surgery occurred, histopathology was
still available, allowing correlation of imaging to assess the
accuracy of imaging characterization. Where surgery was
delayed 3 months for neoadjuvant chemotherapy, CTAP and
 CTAP pMRI
Figure 2 Cyst versus metastasis. Some cysts especially the small ones may appear as indeterminate low attenuation lesions and yet a
have typical fluid signal (arrow on CTAP) and hyperintensity in T2-weighted MRI sequences (arrow on MRI)
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pMRI were repeated prior to surgery to evaluate any change in
disease and ongoing resectability. This was not a significant
deviation from usual practice (Fig. 3).
The group that did not proceed to surgery received systemic
chemotherapy for palliation and were not included in the
analysis.
Statistical analysis
To demonstrate a difference of 10% in the false-positive rate
from the 15% reported for CTAP to 5% for pMRI, with 80%
power and a significance level of 0.05, 160 lesions were needed.
Assuming an average of two lesions per patients, it was esti-
mated 80 patients would need to be recruited.
Data are summarized as the median and interquartile range
for continuous variables and percentages for categorical vari-
ables. As patients can have multiple lesions, sensitivity and
specificity for CTAP and pMRI were computed using lesion
as the unit of analysis. Because lesions are clustered at the
patient’s level, and each patient is observed by two radiolo-
gists, some correlation between observations is expected. Thus,
generalized estimation equations (GEE) with logistic regres-
sion formulation were used to calculate sensitivities and speci-
ficities. An independent working correlation matrix was used
for the GEE.
The diagnostic performance of both radiological tests was
also evaluated for the subgroups of patients who had chemo-
therapy within 6 months prior to scans and patients who had
no chemotherapy in the same time period as well as for
patients with a larger number of lesions (> 6) and patients
with low number of lesions (< 6).
The inter-observer agreement for CTAP and pMRI was mea-
sured using kappa statistics. The significance level was set at
0.05 for all hypothesis tests. The software IBM SPSS (V22.0;
IBM Corp., Armonk, NY, USA) and R 3.1.023 were used for
the statistical analysis.
Ethics
Ethics approval from the Central Network Human Research
Ethics Committee (HREC) was granted for the study: HREC/
10/STG/124. Patient’s consent was obtained in accord with
ethical standards of our HREC.
Results
Eighty-eight patients were initially recruited from July 2011
to May 2013. Of these, only 62 patients underwent an
operation and thus, were eligible for the analysis (Fig. 4).
Two patients had two operations; therefore 64 operations
were performed, and a total of 219 lesions were confirmed
by histopathology. Three patients had radiofrequency
ablation of the liver lesion, so histopathology was not
available.
CRCLM
Resectable
Surgery
histopathology
Neoadjuvant 
chemotherapy
Resectable
Surgery 
histopathology
Not resectable
Compare change 
in size of lesions 
on radiology 
Repeat CTAP/ 
primovist MRI
Not resectable
Palliative 
chemotherapy
Repeat imaging
CTAP/primovist 
MRI
Figure 3 Flowchart of study participants and tests. Colorectal liver metastases (CRCLM), computed tomography during arterial
portography (CTAP), primovist magnetic resonance imaging (pMRI)
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Demographics and details of chemotherapy regimens are
shown in Table 1. The median age of the patients was
64 years, and 63% were male. Twenty-two patients received
chemotherapy within 6 months prior to scans. The details of
the chemotherapy are given in Table 1.
Inter-observer agreement on lesions reported by the four
radiologists is summarized in Table 2.
The sensitivity for lesion detection was similar for pMRI and
CTAP (0.83 versus 0.81, P = 0.642). The specificity of lesion
detection was higher on pMRI, 0.88 than CTAP, 0.83 but did
not reach statistical significance (P = 0.112).
Patients enrolled: 88
Evaluations for CRCLM: 91
Patients analysed: 62
(64 evaluations)
No operation: 26 
Palliative chemo: 17
Neoadjuvant chemo: 5
Refused treatment: 2
No disease seen: 1
Not fit for surgery: 1
Figure 4 Description and reasons of patients excluded from
current analysis. Colorectal liver metastases (CRCLM)
Table 1 Demographic and clinical characteristics of the patients
included in the study (n = 62)
Demographic data
Age, median (IQR) 64 (56–70)
Male, n (%) 39 (63%)
Number of lesions, median (IQR) 2 (1–5)
Chemotherapy within 6 months of scans, n (%) 22 (36%)
Type of chemotherapy
5-Flurouracil Xeloda (with Avastin) 6 (2)
5-Flurouracil Oxaliplatin-based (with Avastin) 13 (6)
5-Flurouracil Irinotecan-based (with Avastin) 2 (1)
Regorafenib (with Avastin) 1 (0)
Planned for 2 stage procedure, n (%) 3 (5%)
Received staged procedure, n (%) 2 (3%)
IQR, interquartile range.
Table 2 Kappa statistics for inter-observer agreement. Computed
tomography during arterial portography (CTAP), primovist
magnetic resonance imaging (pMRI)
Radiologist pMRI 2 CTAP 1 CTAP 2
pMRI 1 0.80(0.74–0.85) 0.75(0.70–0.81) 0.64(0.57–0.70)
pMRI 2 – 0.77(0.72–0.82) 0.66(0.60–0.72)
CTAP 1 – – 0.74(0.68–0.79)
Table 3 Sensitivity and specificity with the respective 95% confidence intervals based on 219 lesions in 62 patients, confirmed by
histopathology
No of patients No of lesions Sensitivity (95% CI) Specificity (95% CI)
CTAP pMRI CTAP pMRI
All patients 62 219 0.81 (0.76; 0.86) 0.83 (0.76; 0.87) 0.83 (0.79; 0.87) 0.88 (0.84; 0.91)
Radiologista
Rater 1 60 214 0.81 (0.73; 0.87) – 0.84 (0.75; 0.90) –
Rater 2 59 213 0.82 (0.73; 0.89) – 0.81 (0.72; 0.88) –
Rater 3 60 212 – 0.82 (0.75; 0.88) – 0.88 (0.81; 0.92)
Rater 4 62 219 – 0.84 (0.78; 0.88) – 0.88 (0.82; 0.92)
Neoadjuvant treatment
Chemotherapy 22 131 0.82 (0.73; 0.88) 0.83 (0.77; 0.87) 0.63 (0.51; 0.73) 0.79 (0.70; 0.86)
No chemotherapy 40 88 0.80 (0.71; 0.86) 0.82 (0.74; 0.88) 0.93 (0.89; 0.95) 0.92 (0.88; 0.95)
Number of lesions
6 or less lesions 52 115 0.80 (0.72; 0.86) 0.84 (0.77; 0.89) 0.86 (0.79; 0.90) 0.89 (0.85; 0.93)
More than 6 lesions 10 104 0.83 (0.74; 0.90) 0.82 (0.76; 0.87) 0.54 (0.40; 0.68) 0.74 (0.58; 0.85)
a
There were some missing observations.
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When stratifying by neoadjuvant chemotherapy treatment,
the sensitivities of CTAP and pMRI were identical in the 22
patients (131 lesions) who had chemotherapy within
6 months prior to scans (0.82 and 0.83, respectively) and the
40 patients (88 lesions) who did not have chemotherapy in
the 6 months period prior to scanning (0.80 and 0.82, respec-
tively). However, the specificity of pMRI was significantly
higher than CTAP for patients who had chemotherapy (0.79
versus 0.63, P = 0.011). For patients with no chemotherapy,
both CTAP and pMRI showed high specificity (0.93 and 0.92,
P = 0.859).
When stratified by the number of lesions identified in the
histopathology, sensitivity and specificity of CTAP and pMRI
were identical for the 52 patients (115 lesions) with 6 or fewer
lesions. However, the specificity of both tests decreased in the
10 patients (104 lesions) with more than six lesions. In this
subgroup, pMRI had a significantly higher specificity than
CTAP (0.74 versus 0.54, P = 0.042) (Table 3).
Discussion
Several findings should be highlighted from this present
study: pMRI showed a good agreement between the two radi-
ologists; operational characteristics of pMRI for the detection
of a liver lesion seem to be, as good as CTAP; for the sub-
group of patients that had chemotherapy within 6 months of
scans, pMRI showed a better specificity compared with
CTAP; and for patients with a large number of lesions (> 6),
an improvement was seen in specificity for pMRI compared
with CTAP.
pMRICTAP    
(A)
(B)
(C)
Figure 5 Post-chemotherapy computed tomography during arterial portography/magnetic resonance imaging (CTAP/MRI). Lesions after
treatment are much more conspicuous on MRI than on CT. Arrows to CRCLM on CTAP and primovist (p)MRI
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The St George unit was uniquely placed to perform such a
comparison as CTAP remained the units standard in the
pre-operative evaluation of patients with CRCLM. The cumu-
lative institutional experience has meant the procedure was
done with a low complication rate, and radiologists were expe-
rienced in the interpretation of results minimizing false-posi-
tives owing to perfusion defects and inexperienced reporting.
Although this is the first study comparing pMRI and CTAP
using histopathology as a gold standard in the context
of CRCLM, several other studies have shown evidence of
good operational characteristics of pMRI in different
contexts.17–19,21,24,25 Interobserver agreement for pMRI was
also reported before (kappa = 0.66)21 but lower than what was
found in this study (kappa = 0.88). This may be explained by
the fact that in this study readers were not blinded to patient’s
history of CRCLM, and this may have increased the accuracy
of the radiologists.
This study found a higher specificity of pMRI compared to
CTAP in the group of patients who received chemotherapy
pre-operatively (and, therefore, pre-scan). There was already
some expectation that pMRI could be more accurate in this
group of patients as hepatobiliary contrast behaviour will be
less affected by steatosis and vascular changes related to che-
motherapy, providing better parenchyma/tumour contrast
owing to hepatocyte uptake of Primovist.26–29 This is clinically
relevant given that CT and CTAP are more difficult to inter-
pret in patients who have had neoadjuvant chemotherapy for
their CRCLM with irinotecan or oxaliplatin. Therefore, the
resulting steatosis, post sinusoidal changes and peliosis affect
liver parenchyma making a contrast-related differentiation
between the liver and tumour more difficult, limiting the accu-
racy of interpretation.30 (Fig. 5)
The incidence of disappearing CRCLM ranges from 5 to
38%.31–33 The inability to observe disappearing CRCLM after
chemotherapy on MRI is strongly associated with a true,
complete response at histology.31 Conversely, the ability to
detect the site of ‘disappearing CRCLM’ at surgery is more
common in patients without pre-operative evaluation with
pMRI suggesting these lesions are not true, complete
responders.31–34 Variability of detection of disappearing
CRCLM at surgery is multifactorial, but the quality of the
pre-operative imaging is a significant factor. These data sug-
gests pMRI may be most suitable for patients with disappear-
ing CRCLM after neoadjuvant chemotherapy to assess
residual disease and delineate patients with a true radiological
complete response.35
There are several limitations to the present study. First, it
is difficult to assess true and false-negative rates in the unre-
sected liver, as only the resected liver is subjected to histo-
pathology assessment.36,37 Ideal assessment of the true and
false-negative rate is possible when the liver is explanted for
histopathology, clearly only possible in a liver transplant
population.38 In the context of CRCLM, association of
findings with radiology, intra-operative assessment and histo-
pathology on a per lesion basis, provide the best available
information for the assessment of sensitivity and specificity
of the two tests compared. However, intraoperative inspec-
tion, palpation and IOUS will not detect deep and small
lesions. IOUS is also an imperfect standard of reference with
sensitivity ranging from 80% to 98%.21,39 False-negative
results occur mainly with superficial subcapsular regions of
the entire liver.25 Follow-up imaging with CT or MRI is also
imperfect, as it requires broad assumptions regarding tumour
doubling times to distinguish between new and pre-existing
micrometastases.21
One important aspect that was not addressed in this study
is the economic evaluation of pMRI. The cost of CTAP is
rebated by Medicare at $A1000perCTAP.40 Primovist MRI is
currently not rebated by Medicare. Patients are asked to pay
for this investigation. The current fee for this procedure var-
ies from A 450 to $A 750, but other factors need to be con-
sidered. There is, therefore, a need for formal cost-
effectiveness analysis of this procedure to address the poten-
tial cost saving related to the shift from CTAP as a standard
diagnostic test to pMRI as the first-line assessment for
CRCLM.
In conclusion, pMRI is a useful diagnostic study in the
assessment of CRCLM and may be a valid alternative to CTAP
given that pMRI is less invasive, of comparable sensitivity and
specificity in the pre-chemotherapy population, demonstrates
better specificity in lesion detection in patients assessed post-
chemotherapy and shows good reproducibility.
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